GenScript ProBio Closes $220M Series C Financing for Biologics and Gene Therapy Expansion
Contract Development and Manufacturing Organization (CDMO) GenScript ProBio has announced the completion of a $220...
Company
Roche and HKSTP Collaborate to Boost Life Sciences in Greater Bay Area
Swiss pharmaceutical giant Roche (SWX: ROG) has signed a multi-faceted collaboration agreement with the Hong...
Burning Rock Upgrades 2022 Revenue Growth Forecast to 10% YOY
Guangzhou-based medical device giant Burning Rock Ltd (NASDAQ: BNR) has issued a notice upgrading its...
Pasithea Therapeutics Partners with WuXi AppTec for API Manufacturing of PAS-004
US-based Pasithea Therapeutics Corp. (NASDAQ: KTTA) has announced that Chinese Contract Research Organization (CRO) WuXi...
CDE Grants Priority Review to Takeda’s Vonicog Alfa, Zhongmei’s Rilonacept, and Zai Lab’s SUL-DUR
The Center for Drug Evaluation (CDE) has indicated that Takeda’s Vonicog alfa, Zhongmei Huadong Pharma’s...
Immunofoco’s CLDN18.2-Targeted CAR-T Therapy IMC002 Accepted for CDE Review
China’s Center for Drug Evaluation (CDE) has accepted a clinical trial filing for IMC002, an...
Keymed Biosciences’ CMG901 Shows Promising Results in Phase Ia Study for Solid Tumors
China-based Keymed Biosciences Inc. (HKG: 2162) has revealed the latest data update from a Phase...
MDHC Group Raises Hundreds of Millions in Third Financing Round
Jiangsu-based MDHC Life Technologies (Kunshan) Co.,Ltd, a leading platform in minimally invasive surgery and life...
Staidson’s STSP-0601 Begins Phase II Study for Hemophilia Treatment
China-based Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204) has announced the first subject dosing in...
Everest Medicines’ EVER206 Shows Positive Phase I Results in China
China-based Everest Medicines (HKG: 1952) has announced top-line results from a Phase I study in...
Bliss Bio Raises RMB 100 Million in Series B+ Financing for Oncology Pipeline
Hangzhou-based oncology-focused clinical-stage biotech Bliss Bio has reportedly raised over RMB 100 million (USD 14.7...
Junshi Biosciences’ Neotorch Study Achieves Superiority in Lung Cancer Trial
Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that its randomized, double-blind, placebo-controlled,...
Hengrui’s EZH2 Inhibitor SHR2554 Nears Breakthrough Therapy Designation
China-based Jiangsu Hengrui Pharmamceuticals (SHA: 600276) has announced that its enhancer for the zeste homolog...
Henlius Terminates TROP2 Antibody Licensing Deal with Chiome Bioscience
Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696) has announced the termination of a licensing deal...
Structure Therapeutics Files for IPO on NASDAQ to Raise $119M
Structure Therapeutics Inc. (Nasdaq: GPCR), a Sino-US firm formerly known as ShouTi Inc., has filed...
Hansoh’s HS-10517 Greenlit for COVID-19 Clinical Study by NMPA
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced receiving approval from the National...
Cowell Health Partners with Gilead Sciences to Enhance Drug Accessibility
Cowell Health has announced a partnership with US-based Gilead Sciences, Inc., (NASDAQ: GILD) aimed at...
IASO Bio Raises RMB 500 Million in Series C1 Funding for Cell Therapy Pipeline
China-based IASO Biotherapeutics has announced the completion of a nearly RMB 500 million (USD 73.7...
Junshi Biosciences’ COVID-19 Drug JT001 (VV116) Accepted for NMPA Review
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that its oral nucleoside analog drug...
Bristol-Myers Squibb’s Opdivo Gains New Indication for NSCLC Neoadjuvant Therapy in China
US-based pharmaceutical giant Bristol-Myers Squibb (BMS, NYSE: BMY) has secured another indication approval in China...